Risk of Cancer in Patients Exposed to Gabapentin in the GPRD
Actual number of patients may be less, as it is possible for a patient to be represented in
more than one of the 22 arms (See "Participant Flow: Overall Study" Table) because of the
risk set sampling.
Observational Model: Case Control, Time Perspective: Retrospective
Number of All-Cancer Cases and Matched Controls With the Indicated Exposure to Gabapentin
Incidence of all cancers. Gabapentin Exposure Description: Without 2 year lag = Gabapentin prescription from cohort entry to index date. With 2 year lag = Gabapentin prescription from cohort entry to 2 years prior to index date (to control for prediagnostic prescribing for pain symptoms possibly related to cancer).
The case index date was the date of incident cancer diagnosis ascertained in the GPRD study cohort 1995-2008. The matched control index date was the date at which the follow-up time from his/her cohort entry was the same as that for the case.
GSK Clinical Trials
United States: No Health Authority